Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Delaware for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Delaware only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Delaware (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Amy Mcghee Jez (NPI 1275976417)

Field	Value
Entity Type	Individual
Organization	Amy Mcghee Jez
Address	4701 Ogletown Stanton Rd
City	Newark
State	DE
ZIP	19713
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	April 8, 2013

Payer Source	Total Paid
Medicare	$1.1M
Medicaid	$0

Key Findings

This provider is heavily revenue-concentrated in a small set of oncology injectables: the precomputed top 3 Medicare codes account for 77.0% of total Medicare revenue, driven by J9271 ($490.2K, 43.0%), J9144 ($328.3K, 28.8%), and J0897 ($60.5K, 5.3%). Those three drug codes together dominate the $1.1M lifetime Medicare revenue, indicating that biologic and monoclonal antibody administrations are the primary revenue drivers for this practice.

The code mix and volumes point to an outpatient infusion/oncology treatment model rather than a primarily office-visit practice: J9271 has 11.4K claims with an average paid/claim of $43 and J9144 has 8.6K claims at $38 avg paid/claim, while chemotherapy administration codes such as 96413 (354 claims, $36.8K) and 96401 (109 claims, $6.3K) also appear on the top list. By contrast, classic E/M codes contribute materially less revenue individually (for example 99215 generated $38.2K), underscoring that drug administration and infusion services drive most billing.

Payer mix is effectively single-payer: Total Medicare revenue is $1.1M and there is no Medicaid billing on file, so this provider’s commercial/Medicaid exposure is absent or not reportable here. That concentration on Medicare means reimbursement and utilization patterns seen in Medicare will largely determine this provider’s observable financial footprint.

Competitive standing across national Medicare peers is mixed: for the highest-revenue code J9271 the provider ranks #1008 of 1841 (44th percentile; characterized as typical, unremarkable volume), and for J9144 the provider ranks #284 of 615 (53th percentile; typical, unremarkable volume), indicating neither national leadership nor scarcity in those drug administrations. There are pockets of relatively higher intensity—J1454 ranks #47 of 422 (88th percentile; typical, unremarkable volume) and 99215 ranks #6592 of 145531 (95th percentile; notably above typical national volume)—which suggest selective areas of above-average utilization within an otherwise typical national footprint.

Coding intensity shows elevated complexity on office visits: 99215 appears with 281 claims, $136 avg paid/claim and $38.2K revenue, and is labeled notably above typical national volume (95th percentile). This pattern—high-complexity E/M billing together with substantial injectable administration—is consistent with managing complex oncology patients in an outpatient infusion setting.

Supportive-care and biosimilar agents are present but represent smaller shares of revenue: Q5122 (pegfilgrastim-apgf) generated $39.2K (3.4%) across 396 claims and ranks #115 of 239 (50th percentile), while J1437 (ferric derisomaltose) produced $25.5K (2.2%) across 1.5K claims and ranks #473 of 581 (15th percentile). These entries indicate routine use of growth-factor support and IV iron, but not at market-leading intensity.

Tenure and scale: the provider’s NPI was enumerated on 2013-04-08 (~13 years ago), establishing a multi-year presence in Medicare billing data that has produced $1.1M in lifetime Medicare revenue. The combination of steady tenure and a drug-centric revenue mix suggests an established oncology practice with ongoing infusion services.

Operational implication of concentration: because a large majority of Medicare revenue is concentrated in a few high-cost injectable codes (notably J9271 and J9144) this provider’s Medicare revenue profile is sensitive to changes in utilization patterns, drug pricing, and coverage policies for those agents. From a payer analytics perspective, monitoring utilization trends and prior-auth patterns for these specific drugs will capture most of the provider’s Medicare-facing activity.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

33 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	11,400	$40	$490.2K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	8,640	$40	$328.3K
J0897	Injection, denosumab, 1 mg	3,360	$20	$60.5K
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	120	$330	$39.7K
Q5122	Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg	400	$100	$39.2K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	280	$140	$38.2K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	350	$100	$36.8K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	290	$90	$26.4K
J1437	Injection, ferric derisomaltose, 10 mg	1,500	$20	$25.5K
99205	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the provider…	60	$160	$9.5K

Showing 1–10 of 33

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 33 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Delaware Distribution

Amy Mcghee Jez — 0 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Delaware

Full comparison — all codes billed, vs. state median

33 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	10	10	17,600	$40	$992.4K
J9144	5	10	9,360	$40	$420.8K
J0897	29	60	3,360	$20	$132.9K
Q5122	3	10	400	$100	$61.8K
J1437	7	10	1,800	$20	$47.1K
J1454	3	10	90	$340	$38.1K
96413	11	30	280	$100	$36.6K
99214	585	1,830	150	$80	$25.5K
96401	15	30	110	$60	$18.4K
99233	441	500	80	$90	$15.4K

Showing 1–10 of 33

Related Providers

Other providers that share a Tax Identification Number (TIN) with Amy Mcghee Jez, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Medical Oncology Hematology Consultants PA	DE	Hematology & Oncology Physician	$0	$7.7M
Jamal Misleh	DE	Hematology & Oncology Physician	$6.8M	$0
Dhaval Shah	DE	Hematology & Oncology Physician	$2.5M	$0
Gregory Masters	DE	Medical Oncology Physician	$2.3M	$0
Evan Lapinsky	DE	Hematology & Oncology Physician	$1.7M	$0
Lydia Clements	DE	Medical Oncology Physician	$1.3M	$0
Sujung Park	DE	Hematology & Oncology Physician	$1.2M	$0
Andrew Himelstein	DE	Hematology & Oncology Physician	$1.1M	$0
Roberto Ferro Valdes	SD	Hematology & Oncology Physician	$1.1M	$0
Martha Hosford Skapof	DE	Hematology & Oncology Physician	$748.2K	$0

Nearby Providers

Other providers in the same ZIP code as Amy Mcghee Jez, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Associated Retinal Consultants LLC	DE	Ophthalmology Physician	$0	$25.2M
Columbus Medical Services, LLC	DE	Case Management Agency	$0	$18.7M
Christiana Care Health Services Inc	DE	Hospitalist Physician	$0	$13.6M
Caritas Home Health Services, Inc	DE	Home Health Agency	$0	$11.2M
Delaware Center For Maternal Fetal Medicine Of Christiana Care	DE	Maternal & Fetal Medicine Physician	$0	$9.8M
Christiana Care Health Services Inc	DE	Neonatal-Perinatal Medicine Physician	$0	$8.9M
Christiana Care Quality Partners	DE	Urgent Care Clinic/Center	$0	$7M
Mid-atlantic Behavioral Health, LLC	DE	Intellectual & Developmental Disabilities Psychologist	$0	$6.5M
First State Orthopaedics, PA	DE	Orthopaedic Surgery Physician	$0	$6M
Autism Delaware	DE	Intellectual & Developmental Disabilities Psychologist	$0	$5.8M

Amy Mcghee Jez — Billing Profile & Reimbursement Data

Sign up for Amy Mcghee Jez — Billing Profile & Reimbursement Data policy alerts

Amy Mcghee Jez — Billing Profile & Reimbursement Data

Sign up for Amy Mcghee Jez — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References